Protagonist Therapeutics PE Ratio 2015-2023 | PTGX
Current and historical p/e ratio for Protagonist Therapeutics (PTGX) from 2015 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Protagonist Therapeutics PE ratio as of June 06, 2023 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Protagonist Therapeutics PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2023-06-06 |
28.91 |
|
0.00 |
| 2023-03-31 |
23.00 |
$-2.84 |
0.00 |
| 2022-12-31 |
10.91 |
$-2.60 |
0.00 |
| 2022-09-30 |
8.43 |
$-2.68 |
0.00 |
| 2022-06-30 |
7.91 |
$-2.74 |
0.00 |
| 2022-03-31 |
23.68 |
$-2.59 |
0.00 |
| 2021-12-31 |
34.20 |
$-2.70 |
0.00 |
| 2021-09-30 |
17.72 |
$-2.41 |
0.00 |
| 2021-06-30 |
44.88 |
$-1.92 |
0.00 |
| 2021-03-31 |
25.90 |
$-1.82 |
0.00 |
| 2020-12-31 |
20.16 |
$-2.00 |
0.00 |
| 2020-09-30 |
19.55 |
$-2.15 |
0.00 |
| 2020-06-30 |
17.66 |
$-2.55 |
0.00 |
| 2020-03-31 |
7.06 |
$-3.14 |
0.00 |
| 2019-12-31 |
7.05 |
$-3.00 |
0.00 |
| 2019-09-30 |
12.01 |
$-2.94 |
0.00 |
| 2019-06-30 |
12.11 |
$-2.71 |
0.00 |
| 2019-03-31 |
12.57 |
$-1.94 |
0.00 |
| 2018-12-31 |
6.73 |
$-1.72 |
0.00 |
| 2018-09-30 |
10.29 |
$-1.30 |
0.00 |
| 2018-06-30 |
6.72 |
$-1.21 |
0.00 |
| 2018-03-31 |
8.59 |
$-1.69 |
0.00 |
| 2017-12-31 |
20.80 |
$-2.17 |
0.00 |
| 2017-09-30 |
17.67 |
$-2.69 |
0.00 |
| 2017-06-30 |
11.31 |
$-3.27 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.655B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
